Memolan Initial

Memantine Hydrochloride, the active ingredient in Memolan Initial, is a NMDA receptor antagonist presented as an oral dosage form for oral use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adults. GNH USA supplies Memolan Initial as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memolan Initial, an NMDA receptor antagonist, is used in the management of Alzheimer’s disease and related cognitive disorders. - Alzheimer’s disease (moderate to severe): improves cognition, functional abilities and overall daily living activities. - Alzheimer’s disease (mild to moderate) combined with a cholinesterase inhibitor: provides additional symptomatic benefit. - Behavioral symptoms in Alzheimer’s disease: may reduce agitation and improve patient cooperation.

Adverse reactions to memantine may vary in frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate cranial pain. - Constipation: reduced bowel movements. - Confusion: transient mental clouding. - Fatigue: feeling unusually tired. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: occurrence of convulsive episodes. - Cardiac arrhythmias: irregular heart rhythms requiring medical attention. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: rare but serious skin disorder.

Before initiating therapy, consider the following safety measures. - Renal impairment: assess kidney function and adjust dose if necessary. - Cardiovascular disease: monitor blood pressure and heart rhythm regularly. - History of seizures: observe for new seizure activity. - Concomitant NMDA antagonists: avoid combined use to reduce neurotoxicity risk. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Memantine may interact with other medications; review patient regimens carefully.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase toxicity. - Ketamine: combined NMDA blockade can lead to excessive CNS effects. - Other NMDA antagonists: heightened risk of neurotoxicity.

Moderate Interactions (Monitor Closely): - Diuretics: may raise plasma memantine concentrations. - Anticholinergics: could worsen cognitive impairment. - CNS depressants: may enhance dizziness or sedation.